MAB4399-I
Anti-CD133 (Prominin-1) Antibody, clone 17A6.1
clone 17A6.1, from mouse
Synonym(s):
Prominin-1, Prominin-like protein 1, Antigen CD133
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
17A6.1, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
western blot: suitable
isotype
IgG2aκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... PROM1(8842)
General description
Prominin-1 (UniProt: O43490; also known as Antigen AC133, Prominin-like protein 1, CD133) is encoded by the PROM1 (also known as PROML1, MSTP061) gene (Gene ID: 8842) in human. CD133 (Prominin-1) is multi-pass cell-surface glycoprotein that plays a role in cell differentiation, proliferation and apoptosis. It binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development CD133 acts as a key regulator of disk morphogenesis. Defects in PROM1 gene are known to cause retinitis pigmentosa, cone-rod dystrophy, and retinal macular dystrophy 2. Higher levels of CD133 have been reported in several cancer cell types, including various leukemias, retinoblastomas, glioblastomas, and kidney carcinomas. Higher levels of CD133 are also observed in pancreatic, gastric, colorectal, and hepatocellular cancers. It is also considered as a marker of stem cells in the adult small intestine that are susceptible to transformation into tumors retaining a fraction of mutant Prom1+ tumor cells. (Ref.: Zhu, L., et al. (2009). Nature 477 (7229); 603-607).
Specificity
Clone 17A6.1 detects recombinant CD133 (Prominin-1) by Western blotting and also detects CD133 (Prominin-1 ) in U251 cells by immunocytochemistry.
Immunogen
GST-tagged recombinat fragment corresponding to 77 amino acids from the N-terminal region of human CD133 (Prominin-1).
Application
Detect CD133 using this mouse monoclonal Anti-CD133 (Prominin-1) antibody, clone 17A6.1, Cat. No. MAB4399-I. Validated for use in Immunocytochemistry.
Immunocytochemistry Analysis: A 1:50 dilution from a representative lot detected CD133 in U251 cells.
Quality
Evaluated by Western Blotting with recombinant Prominin-1.
Western Blotting Analysis: 1 µg/mL of this antibody detected 2.5 µg of recombinant Prominin-1 protein.
Western Blotting Analysis: 1 µg/mL of this antibody detected 2.5 µg of recombinant Prominin-1 protein.
Target description
~97 kDa observed; 97.2 kDa calculated. Uncharacterized bands may be observed in some lysate(s).
Physical form
Format: Purified
Other Notes
Concentration: Please refer to lot specific datasheet.
Not finding the right product?
Try our Product Selector Tool.
recommended
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cong Li et al.
Oncology letters, 22(1), 499-499 (2021-05-14)
Cancer stem cells (CSCs) and epithelial mesenchymal transition (EMT) markers are considered useful indicators associated with metastasis and prognosis of colorectal cancers (CRCs). However, only a few studies have focused on the expression of these useful markers in metastases. Metastasectomy
Naoki Yamashita et al.
Scientific reports, 12(1), 1473-1473 (2022-01-29)
Cancer stem cells (CSCs) are major contributors to the malignant transformation of cells because of their capacity for self-renewal. Aldehyde dehydrogenase1A1 (ALDH1A1) and CD133 are promising candidate of CSC markers in non-small cell lung cancer (NSCLC). Furthermore, TP53 is frequently
Carmen Gil-Gas et al.
Cancers, 15(22) (2023-11-25)
Breast cancer is the leading cause of death among females in developed countries. Although the implementation of screening tests and the development of new therapies have increased the probability of remission, relapse rates remain high. Numerous studies have indicated the
Xiaofei Wang et al.
Oncology reports, 40(1), 241-251 (2018-05-12)
Insufficient radiofrequency ablation (iRFA) often leads to residual hepatocellular carcinoma (HCC) progression. However, the mechanism is still poorly understood. In the present study, we demonstrated that LC3B protein expression levels were significantly increased in the residual hepatocellular carcinoma cells after
Yi Sui et al.
British journal of cancer, 125(7), 1003-1015 (2021-07-12)
Metastasis is the major cause of treatment failure and cancer-related deaths in prostate cancer (PCa) patients. Our previous study demonstrated that a CD44+ subpopulation isolated from PCa cells or tumours possesses both stem cell properties and metastatic potential, serving as
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service